---
title: Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index
  in the era of targeted therapies
date: '2024-04-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38620092/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240416181724&v=2.18.0.post9+e462414
source: Blood
description: 'We evaluated the prognostic value of the Chronic Lymphocytic Leukemia
  International Prognostic Index (CLL-IPI) using a pooled dataset of CLL-patients
  treated first-line with targeted drugs (N=991) or chemoimmunotherapy (N=1,256).
  With a median observation time of 40.5 months, the 3-year progression-free survival
  (PFS)-rates for targeted drug-treated patients varied by CLL-IPI risk group: 96.5%
  (low), 87.6% (intermediate), 82.4% (high), and 78.7% (very high). Differences between
  ...'
disable_comments: true
---
We evaluated the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) using a pooled dataset of CLL-patients treated first-line with targeted drugs (N=991) or chemoimmunotherapy (N=1,256). With a median observation time of 40.5 months, the 3-year progression-free survival (PFS)-rates for targeted drug-treated patients varied by CLL-IPI risk group: 96.5% (low), 87.6% (intermediate), 82.4% (high), and 78.7% (very high). Differences between ...